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analysis of 1187 pregnant women with
different syphilis treatment
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Qiong Feng2, Joseph D. Tucker4,5, Huimin Xia1,6*† and Xiu Qiu1,2,3*†
Abstract
Background: Syphilis is responsible for a substantial burden of preventable adverse outcomes in pregnancy. The
purpose of this study was to compare the frequency of adverse pregnancy outcomes among syphilis-seropositive
women who received different treatment regimens at different times in Guangzhou, China.
Methods: Pregnant women with syphilis infection who received prenatal and delivery services in Guangzhou
between January 2014 and December 2016 were included. Association between treatment status and the
composite adverse outcomes (preterm birth, infant smaller than gestational age, stillbirth, and spontaneous
abortion) was estimated.
Results: Of 1187 syphilis-seropositive pregnant women included in the analysis, 900 (75.8%) syphilis-seropositive
pregnant women received treatment, and 287(24.2%) did not receive treatment. Adverse pregnancy outcomes
were observed among 16.3% (147/900) of women with treatment and 33.8% (97/287) of women without
treatment. Syphilis-seropositive pregnant women treated with one or two courses of penicillin had a similar risk of
adverse pregnancy outcomes (adjusted RR = 1.36, 95% CI: 0.94–1.96). Adverse outcomes were more common
among women whose non-treponemal serum test titer was >1:8 and received treatment after 28 weeks compared
to before 28 weeks (adjusted RR = 2.34, 95% CI: 1.22–4.48).
Conclusions: Women who received one course of penicillin and women who received two courses of penicillin
had a similar risk of adverse pregnancy outcomes. Syphilis treatment before 28 weeks of pregnancy is critical.
Strategies to promote high-quality prenatal services are needed.
Keywords: Syphilis, Treatment, Adverse outcomes, Pregnant women
Background
Approximately one million pregnant women are infected
with syphilis each year [1]. Many of these women do not
receive testing and treatment, constituting a major
missed public health opportunity. Syphilis in pregnancy
causes stillbirth, neonatal death, prematurity, low birth
weight, and congenital syphilis [2, 3].
As an epicenter of the global syphilis epidemic, China
has a heavy burden of syphilis among pregnant women
[4, 5]. Data from the Chinese national surveillance
system and World Health Organization both suggest the
prevalence of syphilis infection among pregnant women
in China is between 0.3–1.0% [6–8]. For example, in
2013, the Chinese national surveillance system reported
15,884 cases of syphilis among pregnant women who
delivered, 55.6% (8829) of these cases tested positive
during pregnancy and 43.8% (6968) tested positive at
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labor [9]. To prevent mother-to-child transmission of
syphilis, the Chinese government established the
Integrated Prevention of Mother-to-Child Transmission
(IPMTCT) system. The system provides opt-out, free
syphilis, HIV, and hepatitis B testing at the first prenatal
visit and at delivery [10, 11]. Women diagnosed with
syphilis are provided free treatment. In addition, China
has a comprehensive longitudinal maternal health
system that accurately captures data describing adverse
outcomes and treatment [12]. The city of Guangzhou
has all medical institutions covered by the IPMTCT
system and enhanced monitoring. This provides a strong
opportunity for research to better understand syphilis
treatment among pregnant women.
Previous research on maternal syphilis in China
focused on the relatively rare outcome of congenital
syphilis and not the large spectrum of adverse pregnancy
outcomes known to be associated with syphilis infection
[3]. Moreover, most of our knowledge about syphilis out-
comes in pregnancy comes from small observational
studies or from the pre-penicillin era [2, 13, 14]. The
purpose of this study was to compare the frequency of
adverse pregnancy outcomes among syphilis-seropositive
women who received different treatment regimens at
different times in Guangzhou, China.
Methods
Study design and participants
This retrospective cohort study used data within the
Guangzhou IPMTCT system. Between January 2014 and
December 2016, a total of 1391 (out of 7,009,069; 0.02%)
pregnant women who received pregnancy and delivery
care services in Guangzhou were diagnosed with syphilis
and reported to the IPMTCT system. Syphilis-seropositive
pregnant women who elected to terminate their preg-
nancy (n = 94), with ectopic pregnancy (n = 31), with twin
or multiple gestation pregnancies (n = 30), with absent in-
formation to indicate if they received syphilis treatment or
not (n = 45), and with incomplete outcome information
(n = 4) were excluded. A total of 1187 women were
included in this analysis (Fig. 1). The dataset of the
Guangzhou IPMTCT system belong to the Guangzhou
Women and Children’s Health Information Center. The
data was anonymised and subsequently, consent require-
ment was waived and participatory consent was obtained
by the GuangzhouWomen and Children’s Medical Center
Ethics Approval Board (2017072601).
Diagnosis of syphilis in pregnancy
A diagnosis of syphilis required a positive treponemal test
and a positive non-treponemal antibody test. Treponemal
tests included treponema pallidum particle agglutination
assay (TPPA) and enzyme linked immunosorbent assay
(ELISA). Non-treponemal serum tests included toluidine
red unheated serum test (TRUST) and rapid plasma
reagin (RPR).
Treatment for prevention of mother-to-child transmission
of syphilis
According to national guidelines, syphilis-seropositive
pregnant women should be provided with two courses
of syphilis treatment for prevention of mother-to-child
transmission [15]. A single complete course includes
either benzathine penicillin 2.4 million units intramuscu-
larly per week for three consecutive weeks or procaine
penicillin 0.8 million units intramuscularly daily for 15
consecutive days. Ceftriaxone (1 g intravenous or intra-
muscularly daily for 10 consecutive days) may be used as
an alternative to penicillin. For women who are allergic
to penicillin, erythromycin (500 mg orally 4 times daily
for 15 consecutive days) may be used.
The study divided participants into four groups based
on syphilis treatment completed during pregnancy: (1)
two courses: completed two full treatment courses dur-
ing pregnancy, with an interval of more than one week
between each other; (2) one course: completed at least
one treatment course during pregnancy, but less than
two full courses; (3) insufficient treatment: completed
less than one full treatment course or patients who had
information indicating they received treatment but
without data confirming treatment completion; (4) no
treatment. In addition, women were divided into four
groups based on gestational age at treatment initiation
and medication given: (1) penicillin treatment initiated
before 28 weeks gestation; (2) penicillin treatment initi-
ated at or after 28 weeks gestation; (3) non-penicillin
treatment; (4) no treatment.
Adverse outcomes and definitions
The primary outcome of the study was a composite
adverse pregnancy outcome that included the following:
(1) preterm birth: live birth delivered between 24 and < 37
weeks gestational age; (2) small for gestational age infant
(SGA): birth weight < 10th percentile, based on the Inter-
national Fetal and Newborn Consortium for the
twenty-first Century criteria [16]; (3) stillbirth: fetal death
at or after 28 weeks gestation or intrapartum death; and
(4) spontaneous abortion: defined as spontaneous
pregnancy loss before 28 weeks gestation. We chose not
to include congenital infection in this manuscript for the
following reasons: many clinics lack the knowledge and
diagnostics required to make an accurate congenital
syphilis diagnosis, resulting in misclassification bias [17];
stillbirth, preterm birth, and the other adverse outcomes
are responsible for substantial morbidity according to
disability-adjusted life-year estimates [18, 19]; other
studies have focused on congenital syphilis and maternal
interventions in China [3].
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Information on pregnancy outcomes was reported by
the hospital where participants gave birth. Delivery data
(including delivery date, gestational age, gender, birth
weight, live birth status) were obtained through the elec-
tronic Guangzhou Perinatal Health Care and Delivery Sur-
veillance System (GPHCDSS). The Guangzhou database
was started in 2000 and covers 99% all delivering mothers
and infants in Guangzhou. Information from the IPMTCT
and GPHCDSS databases can be linked through matching
maternal ID and name [16]. In both systems, gestational
age at birth was expressed as completed weeks and was
based on first- or second-trimester ultrasound. In the ab-
sence of a recorded ultrasound data, last menstrual period
was used to calculate gestational age.
Statistical analysis
Descriptive analysis was used to summarize socio-demo-
graphic information of study participants. Chi-squared
tests were used to compare socio-demographic informa-
tion and clinical characteristics of participants. T-test
was only used to analyze age. Non-penicillin treatment
cases were described, but not further analyzed because
of small sample sizes. Binomial regression models were
used to analyze correlations of syphilis-seropositive
pregnant women receiving different treatment regimens
and adverse pregnancy outcomes, and with different
non-treponemal serum test titers and adverse pregnancy
outcomes, with corresponding relative risk (RR) and 95%
confidence intervals (CI) reported and adjusted for po-
tential confounders (maternal age, marital status, house-
hold registration, parity, treatment status and treatment
start time during pregnancy). We further examined the
relationships between different treatments and adverse
pregnancy outcomes, stratifying for non-treponemal
serum test titer. All analyses were conducted using SAS
version 9.3 (SAS Institute, Cary, USA). Significance was
set as α = 0.05.
Results
Participants
Among the included 1187 participants, 244 (21.2%) of
participants had at least one composite adverse
pregnancy outcome, including 17 (1.4%) spontaneous
abortions, 24 (2.0%) still births, 125 (10.5%) preterm
births, and 86 (7.2%) SGAs (Table 1).
Figure 2 shows the dose-response of non-treponemal
serum test titers and adverse outcomes among
syphilis-seropositive pregnant women in Guangzhou.
Maternal age, marital status, household registration, par-
ity and treatment status were adjusted in this model.
Fig. 1 Sample size flow chart of study participants (Guangzhou, China, 2014–2016)
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Given the size of subgroups, we grouped the
non-treponemal serum test titers variable into “≤ 1:8”
and “>1:8”. Women whose non-treponemal serum test
titers were >1:8 had higher rate of adverse outcome
compared to women with titers ≤1:8 (adjusted RR = 1.60,
95% CI: 1.25–2.05).
Participant characteristics were compared between
women with and without adverse outcomes (Table 2).
The mean age of these participants was 30.2 (standard
deviation 5.9) years old. The majority of the participants
were migrants (839, 70.6%) and diagnosed in a public
hospital (1016, 85.6%). 402 (33.9%) participants were di-
agnosed with syphilis at or after 28 weeks gestation, of
which 200 (16.8%) were diagnosed at delivery. Among
the included 1187 women, 682 (57.4%) initiated penicil-
lin treatment before 28 weeks gestation, 200 (16.8%) ini-
tiated treatment at or after 28 weeks gestation, 18 (1.5%)
received non-penicillin treatment, and 287 (24.2%) did
not receive any treatment during pregnancy. The median
gestational age at delivery for live births was 39 weeks.
The age of syphilis-seropositive pregnant women with
adverse pregnancy outcomes was lower than those
without adverse pregnancy outcomes (29.1 vs 30.5, p <
0.001). Syphilis-seropositive pregnant women who were
unmarried, diagnosed at or after 28 weeks of pregnancy,
going to the suburban hospital and with no treatment
were more likely to have adverse outcomes (p < 0.05).
Relative risk of adverse pregnancy outcomes by
treatment status
Associations between syphilis treatment regimens and
the composite adverse pregnancy outcomes are shown
in Table 3. Two-hundred forty-one women had an
adverse pregnancy outcome. Among these women, 109
(16.0%) were treated with penicillin before 28 weeks
gestation, 35 (17.5%) were treated with penicillin at or
after 28 weeks gestation, and 97 (33.8%) were untreated.
After adjusting for covariates, adverse outcomes were
similar among the women treated with penicillin before
28 weeks gestation and those treated at or after 28
weeks gestation (adjusted RR = 1.13, 95% CI: 0.79–
1.61, p = 0.471). Adverse outcomes were significantly
more common among those without treatment com-
pared to those treated with penicillin before 28 weeks
gestation (adjusted RR = 2.07, 95% CI: 1.59–2.68).
After adjusting for covariates, when compared to
those treated with two courses of penicillin, adverse
outcomes were similar among the women treated
with one course of penicillin (adjusted RR = 1.36, 95%
CI: 0.94–1.96).
Table 1 Adverse pregnancy outcomes of study participants in
Guangzhou, China, 2014–2016
Adverse pregnancy outcomes N (%)
No 943 (78.8)
Yes 244 (21.2)
Spontaneous abortion 17 (1.4)
Still birth 24 (2)
Preterm birth 125 (10.5)
SGAa,b 86 (7.2)
Abbreviations: SGA small for gestational age infant
aBased on INTERGROWTH-21st criteria
bIncluding 8 preterm births
Fig. 2 Risk of composite adverse outcome among syphilis-seropositive pregnant women by non-treponemal serum test titers (Guangzhou,
China, 2014–2016)
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Among participants with non-treponemal serum test
titers ≤1:8, after adjusting for covariates, adverse
outcome was similar between women treated at or
after 28 weeks gestation compared to those treated
before 28 weeks gestation (adjusted RR = 0.91, 95% CI:
0.60–1.38) (Table 4). Among participants with
non-treponemal serum test titer >1:8, after adjusting
for covariates, incidence of adverse outcomes was sig-
nificantly higher among those treated at or after 28
weeks gestation compared to those treated with peni-
cillin before 28 weeks gestation (adjusted RR = 2.34,
95% CI: 1.22–4.48).
Discussion
This retrospective cohort study examined associations
between syphilis treatment regimens and adverse preg-
nancy outcomes among pregnant women with syphilis.
We found that adverse outcomes were more common
among women with non-treponemal serum test titers
>1:8 who received penicillin treatment after 28 weeks of
pregnancy. We observed syphilis-seropositive pregnant
women who received one or two courses of penicillin
treatment had similar rates of adverse pregnancy
outcomes. Our study advances the literature by examin-
ing a composite adverse outcome (instead of a single
Table 2 Participant characteristics compared across syphilis-seropositive pregnant women with and without adverse pregnancy
outcomes in Guangzhou, China, 2014–2016
Variables All women
N
Women without
adverse outcomes
N (%)
Women with
adverse outcomes
N (%)
χ2 p
Age (Mean, SD, years) 30.2 ± 5.9 30.5 (5.8) 29.1 (6.4) 3.340a < 0.001
Household registration
Local 348 284 (81.6) 64 (18.4) 1.413 0.235
Migrant 839 659 (78.6) 180 (21.5)
Marital status
First marriage 944 775 (82.1) 169 (17.9) 26.466 < 0.001
Unmarried 136 86 (63.2) 50 (36.8)
Others 107 82 (76.6) 25 (23.4)
Public hospital
Yes 1016 831 (81.8) 185 (18.2) 0.055 0.815
No 171 112 (65.5) 59 (34.5)
Hospital area
Urban 383 308 (80.4) 75 (19.6) 8.481 0.014
Suburban 417 313 (75.1) 104 (24.9)
Rural 387 322 (83.2) 65 (16.8)
Time of syphilis diagnosis
< 28 weeks of gestation 785 655 (83.4) 130 (16.6) 22.659 < 0.001
≥ 28 weeks of gestation 402 288 (71.6) 114 (28.4)
Syphilis infection stage
Latent 958 755 (78.8) 203 (21.2) 1.375 0.503
Stage I-II 72 58 (80.6) 14 (19.4)
Unknown 157 130 (82.8) 27 (17.2)
Non-treponemal serum test titer
≤ 1:8 1016 831 (81.8) 185 (18.2) 23.796 < 0.001
>1:8 171 112 (65.5) 59 (34.5)
Treatment status
No treatment 287 190 (66.2) 97 (33.8) 40.863 < 0.001
Penicillin treatment < 28 weeks gestation 682 573 (84) 109 (16)
Penicillin treatment ≥28 weeks gestation 200 165 (82.5) 35 (17.5)
Non-penicillin treatment 18 15 (83.3) 3 (16.7)
Abbreviations: SD standard deviation
aT-test
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outcome) with a large sample size, integrating two
high-quality data sources, and leveraging China’s
extensive maternal child health system.
Our study has shown that adverse outcomes were
more common among those whose non-treponemal
serum test titer was >1:8 and received penicillin
treatment after 28 weeks of pregnancy. This suggests
that one course of penicillin before 28 weeks of
pregnancy is critical for preventing adverse outcomes of
syphilis, while there is the potential for T. pallidum
Table 3 Risk of composite adverse outcomes among syphilis-seropositive pregnant women by syphilis treatment status in
Guangzhou, China, 2014–2016a
Treatment during pregnancy Women with adverse
outcomes, N (%)
Crude RR (95% CI) Adjusted RR (95% CI)
Treatment initiation
Penicillin <28w 109 (16) reference reference
Penicillin ≥28w 35 (17.5) 1.10 (0.77–1.55) 1.13 (0.79–1.61) b
No treatment 97 (33.8) 2.11 (1.67–2.68) 2.07 (1.59–2.68) b
Treatment course
2 courses 73 (14.2) reference reference
1 course 38 (17.8) 1.26 (0.88–1.80) 1.36 (0.94–1.96)c
Insufficient treatment 33 (21.3) 1.50 (1.04–2.17) 1.58 (1.08–2.31)c
No treatment 97 (33.8) 2.38 (1.82–3.11) –
Abbreviations: RR relative risk, CI confidence intervals
aNone-penicillin treatment cases were excluded
bAdjusted for age, marital status, household registration, and multipara status
c Adjusted for age, marital status, household registration, multipara status, and the start time of treatment in the gestation
Table 4 Risk of composite adverse outcome among syphilis-seropositive pregnant women with different non-treponemal serum
test titers by syphilis treatment status in Guangzhou, China, 2014–2016 a
Treatment during pregnancy Women with adverse outcomes, N (%) Crude RR (95% CI) Adjusted RR (95% CI)
Non-treponemal serum test titers ≤1:8 (N = 999)
Treatment initiation
Penicillin < 28w 95 (10.6) reference reference
Penicillin ≥28w 25 (34.6) 0.88 (0.59–1.33) 0.91 (0.60–1.38)b
No treatment 63 (41.7) 1.73 (1.31–2.28) 1.77 (1.31–2.40)b
Treatment course
2 courses 67 (14.9) reference reference
1 course 31 (16.2) 1.09 (0.74–1.61) 1.21 (0.82–1.81)c
Insufficient treatment 22 (16.9) 1.14 (0.73–1.77) 1.22 (0.78–1.91)c
No treatment 63 (27.6) 1.86 (1.37–2.52) –
Non-treponemal serum test titers >1:8 (N = 170)
Treatment initiation
Penicillin <28w 14 (15.9) reference reference
Penicillin ≥28w 10 (43.5) 2.73 (1.40–5.34) 2.34 (1.22–4.48)b
No treatment 34 (57.6) 3.62 (2.14–6.14) 2.93 (1.66–5.17)b
Treatment course
2 courses 6 (14.7) reference reference
1 course 7 (31.3) 3.39 (1.28–9.02) 2.19 (0.90–5.31)c
Insufficient treatment 11 (50.0) 4.69 (1.95–11.32) 2.40 (1.05–5.52)c
No treatment 34 (63.4) 6.15 (2.78–13.58) –
Abbreviations: RR relative risk, CI confidence intervals
aNone-penicillin treatment cases were excluded
bAdjusted for age, marital status, household registration, and multipara status
cAdjusted for age, marital status, household registration, multipara status, and the start time of treatment in the gestation
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transmission from mother to child as early as 9–10
weeks gestation [20], our data suggest that treatment
before 28 weeks gestation can avert a large burden of
adverse outcomes.
Compared to two courses of treatment, one course of
penicillin had similar rates of adverse outcomes in this
study. Chinese national guidelines recommend two
courses of intramuscular benzathine penicillin, with each
course consisting of one shot per week for three weeks
[15]. However, national guidelines are often not followed
in clinical practice. Our study found only half of preg-
nant women treated for syphilis received treatment that
met national guidelines. Although our study was not
designed to establish non-inferiority between one and
two courses, it suggests that one course may be reason-
able, at least for preventing adverse outcomes included
in our study.
Our data also suggest most syphilis-seropositive preg-
nant women were migrant women. Migrant women have
worse pregnancy outcomes compared to pregnant
women from Guangzhou. Our study is consistent with
previous literature showing worse pregnancy outcomes
among migrants in China and Italy [21–23]. The lack of
or inability to access services may explain why migrant
pregnant women with syphilis in our study had delayed
screening and lower treatment rates. Poverty, lack of
health insurance, and inability to recoup health insur-
ance benefits in large cities may be barriers to receiving
ANC services for migrant pregnant women [23, 24].
Strategies to improve access to pregnancy care, guaran-
tee similar quality of ANC services across different
settings, expand insurance coverage, and promote syph-
ilis testing may be useful to address this problem.
There are several limitations in this study. First, we
only included data from a single large city. Guangzhou
is the provincial hub and has greater resources and
better infrastructure for screening and treating syphilis
in pregnancy than most other settings in China. Second,
although all women were screened for HIV infection, we
do not have data describing other sexually transmitted
co-infections which could also cause adverse outcomes
in pregnancy. Third, pregnant women in China often re-
ceive care at several hospitals and by multiple physicians.
As a result, making inferences about the influence of
specific hospitals or physicians is challenging. However,
in this study, we successfully linked all reported cases.
Fourth, few women were treated with ceftriaxone, a drug
that may be useful for women who are allergic to
penicillin [25]. Fifth, initial infection and re-infection
cannot be differentiated based on syphilis serology alone,
and therefore our study could not make inferences
regarding re-infection rates among pregnant women.
Finally, we did not differentiate outcomes based on
when patients were diagnosed.
This study has several research and policy implica-
tions. Further implementation research is needed to
improve screening and expand treatment. Quality im-
provement measures to enhance early syphilis testing
and timeliness of treatment following early syphilis test-
ing among all women should be further investigated.
Given the inherent ethical dilemmas of studies with
comparator arms, further cohort research may be most
appropriate. Modeling research to suggest particular
policy strategies may also be useful. At the policy level,
packages of services for women, especially for migrant
women, are needed. Strategies to simplify and better
integrate current syphilis treatment programs are also
required.
Conclusions
Our study reveals adverse outcomes were similar
between syphilis-seropostive pregnant women who
received one or two courses of penicillin treatment and
treatment before 28 weeks gestation can avert a large
burden of adverse outcomes. The results of our study
have practical implications for the prevention and treat-
ment syphilis-attributable adverse pregnancy outcomes.
Strategies are warranted to promote higher-quality, more
comprehensive prenatal healthcare services.
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